PHAXIAM THERAPEUTICS S.A. Inactive Instrument
PHAXIAM Therapeutics S.A. Stock Nasdaq
Equities
ERYP
US29604W2070
Biotechnology & Medical Research
| Sales 2024 * | 1.05M 1.13M 1.54M | Sales 2025 * | 1.6M 1.71M 2.35M | Capitalization | 17.98M 19.27M 26.38M |
|---|---|---|---|---|---|
| Net income 2024 * | - 0 0 | Net income 2025 * | 1M 1.07M 1.47M | EV / Sales 2024 * | 17.6 x |
| Net Debt 2024 * | 450K 482K 660K | Net Debt 2025 * | 10.55M 11.31M 15.48M | EV / Sales 2025 * | 17.8 x |
| P/E ratio 2024 * |
-2.1
x | P/E ratio 2025 * |
-3.12
x | Employees | 68 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 92.14% |
More Fundamentals
* Assessed data
More news
Latest transcript on PHAXIAM Therapeutics S.A.
More press releases
More news
| Managers | Title | Age | Since |
|---|---|---|---|
Thibaut du Fayet
CEO | Chief Executive Officer | 56 | 23-06-22 |
Eric Soyer
DFI | Director of Finance/CFO | 57 | 23-06-22 |
Pascal Birman
CTO | Chief Tech/Sci/R&D Officer | - | 23-06-22 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 63 | 23-06-22 | |
Hilde Windels
BRD | Director/Board Member | 59 | 23-06-22 |
Gil Beyen
BRD | Director/Board Member | 62 | 23-06-22 |
PHAXIAM Therapeutics S.A. is a biopharmaceutical company developing innovative treatments for resistant bacterial infections, responsible for many serious infections. The company relies on an innovative approach based on the use of phages, natural bacteria-killing viruses. PHAXIAM Therapeutics S.A. is developing a portfolio of phages targeting 3 of the most resistant and dangerous bacteria, which alone account for more than two-thirds of resistant nosocomial infections: Staphylococcus aureus, Escherichia coli and Pseudomonas aeruginosa.
Calendar
2024-05-14
- Q1 2024 Earnings Release
| 1st Jan change | Capi. | |
|---|---|---|
| -1.13% | 104B | |
| +6.56% | 97.47B | |
| +5.71% | 22.25B | |
| -12.98% | 21.68B | |
| -9.70% | 18.2B | |
| -39.98% | 17.02B | |
| -10.68% | 16.36B | |
| +8.33% | 14.39B | |
| +39.53% | 12.37B |
